טוען...
Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis
BACKGROUND AND AIMS: This GEMINI 1 post hoc analysis evaluated vedolizumab efficacy for inducing deep remission in patients with ulcerative colitis and correlation between vedolizumab trough concentrations and deep remission rates. METHODS: Week 6 vedolizumab responders were re-randomized to placebo...
שמור ב:
| הוצא לאור ב: | J Crohns Colitis |
|---|---|
| Main Authors: | , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Oxford University Press
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6357899/ https://ncbi.nlm.nih.gov/pubmed/30285104 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ecco-jcc/jjy149 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|